Lokahi Therapeutics, Inc. completed its reverse merger with GlucoTrack, Inc. (Nasdaq: GCTK) on July 14, 2026, with Lokahi becoming a wholly owned subsidiary and the operating business of the combined publicly traded company. Under the terms of the transaction, Lokahi securityholders received a combination of GlucoTrack common stock and convertible preferred stock and are expected to own approximately 90% of the combined company on a fully diluted basis following the receipt of required stockholder approvals and the conversion of the preferred stock, subject to transaction-related financing and customary adjustments.
Concurrently with the merger, the company completed a related bridge note financing with E.F. Hutton & Co. serving as the exclusive financial advisor and placement agent. The financing was executed alongside the merger closing to provide immediate capital to support the combined company’s strategic initiatives and growth plans.
Lucosky Brookman LLP served as legal counsel to Lokahi Therapeutics, Inc. in connection with the reverse merger transaction and related bridge note financing.
